Protective Effects of Cannabidiol against Seizures and Neuronal Death in a Rat Model of Mesial Temporal Lobe Epilepsy by Raquel A. Do Val-da Silva et al.
fphar-08-00131 March 20, 2017 Time: 19:28 # 1
ORIGINAL RESEARCH
published: 17 March 2017
doi: 10.3389/fphar.2017.00131
Edited by:
Andrew C. McCreary,
Janssen Prevention Center,
Netherlands
Reviewed by:
Avital Schurr,
University of Louisville, USA
Víctor Fernández-Dueñas,
University of Barcelona, Spain
*Correspondence:
Joao P. Leite
jpleite@fmrp.usp.br
†These authors have contributed
equally to this work.
Specialty section:
This article was submitted to
Neuropharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 20 December 2016
Accepted: 02 March 2017
Published: 17 March 2017
Citation:
Do Val-da Silva RA, Peixoto-Santos
JE, Kandratavicius L, De Ross JB,
Esteves I, De Martinis BS, Alves MNR,
Scandiuzzi RC, Hallak JEC, Zuardi
AW, Crippa JA and Leite JP (2017)
Protective Effects of Cannabidiol
against Seizures and Neuronal Death
in a Rat Model of Mesial Temporal
Lobe Epilepsy.
Front. Pharmacol. 8:131.
doi: 10.3389/fphar.2017.00131
Protective Effects of Cannabidiol
against Seizures and Neuronal Death
in a Rat Model of Mesial Temporal
Lobe Epilepsy
Raquel A. Do Val-da Silva1†, Jose E. Peixoto-Santos1†, Ludmyla Kandratavicius1,2,
Jana B. De Ross1, Ingrid Esteves1, Bruno S. De Martinis2,3, Marcela N. R. Alves3,
Renata C. Scandiuzzi1, Jaime E. C. Hallak1,2, Antonio W. Zuardi1,2, Jose A. Crippa1,2 and
Joao P. Leite1,2*
1 Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of São Paulo,
São Paulo, Brazil, 2 National Institute of Science and Technology for Translational Medicine, Conselho Nacional de
Desenvolvimento Cientifico e Tecnologico, Brasília, Brazil, 3 Department of Chemistry, Faculty of Philosophy, Science and
Languages of Ribeirao Preto, University of São Paulo, São Paulo, Brazil
The present study reports the behavioral, electrophysiological, and neuropathological
effects of cannabidiol (CBD), a major non-psychotropic constituent of Cannabis sativa,
in the intrahippocampal pilocarpine-induced status epilepticus (SE) rat model. CBD
was administered before pilocarpine-induced SE (group SE+CBDp) or before and
after SE (group SE+CBDt), and compared to rats submitted only to SE (SE group),
CBD, or vehicle (VH group). Groups were evaluated during SE (behavioral and
electrophysiological analysis), as well as at days one and three post-SE (exploratory
activity, electrophysiological analysis, neuron density, and neuron degeneration).
Compared to SE group, SE+CBD groups (SE+CBDp and SE+CBDt) had increased
SE latency, diminished SE severity, increased contralateral afterdischarge latency and
decreased relative powers in delta (0.5–4 Hz) and theta (4–10 Hz) bands. Only
SE+CBDp had increased vertical exploratory activity 1-day post SE and decreased
contralateral relative power in delta 3 days after SE, when compared to SE group.
SE+CBD groups also showed decreased neurodegeneration in the hilus and CA3,
and higher neuron density in granule cell layer, hilus, CA3, and CA1, when compared
to SE group. Our findings demonstrate anticonvulsant and neuroprotective effects of
CBD preventive treatment in the intrahippocampal pilocarpine epilepsy model, either as
single or multiple administrations, reinforcing the potential role of CBD in the treatment
of epileptic disorders.
Keywords: epilepsy, cannabidiol, neuroprotection, intrahippocampal pilocarpine, animal model
INTRODUCTION
Epilepsy is a disease characterized by spontaneous, recurrent seizures and the neurobiological,
cognitive, behavioral, psychological, and social changes associated with the seizures (Fisher et al.,
2014). While significant advances occurred on pharmacological treatments in the last century, up
to 35% of patients with epilepsy do not respond to currently available drug treatments, especially
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temporal lobe epilepsy (TLE) patients with hippocampal sclerosis
(Mohanraj and Brodie, 2006). TLE patients often present with
severe neuron loss in CA1 and hilus subfields, poor verbal
and non-verbal memory associated with the neuron loss, and
neuropathological reorganization of synaptic connections within
the hippocampus (Babb et al., 1991; Blumcke et al., 2013;
Rodrigues et al., 2015; Peixoto-Santos et al., 2017). Additionally
to the burden of seizures in the patient’s quality of life (Devinsky
et al., 1995; Engel, 1996), uncontrolled seizures are known to
promote neuron loss over time (Mathern et al., 2002), which
could increase the cognitive deficits already seen in these patients
(Rodrigues et al., 2015).
Cannabidiol (CBD), a non-psychotropic derivative of
Cannabis sativa, is a promising candidate for the treatment
of drug-resistant epilepsies. Although CBD was first isolated
in 1940 and had its structure described in 1963 (Mechoulam
and Hanus, 2000), the precise mechanisms of action and its
interaction with the endocannabinoid system are still poorly
understood. In the central nervous system, CBD is a low-affinity
inverse agonist of the endocannabinoid receptor CB1 and also
acts in several neurotransmitters receptors and ionic channels
(Consroe et al., 1982; Pertwee, 2008; Jones et al., 2012; Hofmann
and Frazier, 2013; Devinsky et al., 2014). Besides its direct effects
on neurotransmission, studies in several animal models and
human patients have indicated anti-inflammatory, antioxidant,
anxiolytic, and neuroprotective action of CBD in the central
nervous system (Hampson et al., 1998; Braida et al., 2003;
Campos and Guimaraes, 2008; Jones et al., 2012). Following
case reports of subjects who smoked cannabis to treat epilepsy
(Consroe et al., 1975; Ellison et al., 1990), the effects of CBD on
seizure control were increasingly explored. In fact, CBD’s very
first observed effect in animal model was the anticonvulsant
action (Carlini et al., 1973). After the initial animal observations,
double-blind clinical studies showed anticonvulsant effects
of CBD, with reduction of seizure frequency in patients with
drug-resistant epilepsy (Cunha et al., 1980; Trembly and
Sherman, 1990). More recently, CBD use as an add-on to
conventional antiepileptic drug regimen was shown to reduce
seizure frequency in severe drug-resistant epilepsies (Devinsky
et al., 2016).
Animal models of epilepsy reproduce in great extent the
symptoms and phenotypes associated with the human disease
(Kandratavicius et al., 2014a). For instance, increased pre-ictal
delta and theta oscillations seen in the perforant path rat model of
TLE (Broggini et al., 2016) are similar to the oscillatory changes
seen in TLE patients (Baulac, 2015; Malter et al., 2016). Moreover,
changes in low-frequency oscillations can contribute to seizure
initiation (Nazer and Dickson, 2009; Grasse et al., 2013). This
similarity allowed the evaluation of the anticonvulsant effects of
CBD in several animal models, such as the seizures induced by
electroconvulsant currents, pentylenetetrazole-induced seizures,
pilocarpine-induced seizures, and others (Karler and Turkanis,
1981; Consroe et al., 1982; Jones et al., 2009, 2012; Mao et al.,
2015). For instance, CBD showed electrographic protection
in electrically induced kindling and pentylenetetrazole, with
decreased amplitude and duration of epileptiform local field
potentials (LFPs), and increased threshold for afterdischarges
(Turkanis et al., 1979; Jones et al., 2009). Additionally, studies
on other nervous system disorders suggested that CBD has
a neuroprotective effect (Braida et al., 2003; Mechoulam and
Shohami, 2007; Hayakawa et al., 2008; Sagredo et al., 2011;
Fernandez-Ruiz et al., 2013; Campos et al., 2016). However,
there is still limited data regarding CBD effects on the
neuropathological changes seen in the latent phase of epilepsy
models.
Thus, the present study was designed to investigate the
anticonvulsant and neuroprotective effects of CBD in the
pilocarpine-induced status epilepticus (SE) rat model. We tested
the effects of 10 mg/kg i.p. CBD before SE (CBD preventive
treatment, SE+CBDp) and before and after SE (CBD preventive
and therapeutic treatment, SE+CBDt) using behavioral analysis,
electrophysiological analysis, and examining neuropathological
hippocampal changes during SE and at short-term latent phase
after SE (1 and 3 days after SE).
MATERIALS AND METHODS
Animals
Wistar male rats (2 months old, 260–300 g; from the Central
Animal Laboratory of Ribeirao Preto Medical School) were
housed at room temperature (25 ± 2◦C), 12:12 light/dark
cycle (lights on at 7 a.m.), and free access to food and
water. All procedures were performed in agreement with
the ethical principles of animal experimentation adopted by the
Brazilian College of Animal Experimentation (COBEA) and
approved by the Ethics Committee on Animal Experiments
(CETEA) of Ribeirao Preto Medical School (protocol
#051/2010).
Surgery and Treatments
Rats were anesthetized with ketamine hydrochloride 10%
(0.5 ml/kg i.p. + 0.75 ml/kg i.m.; Agener, Brazil) and xylazine
(0.25 ml/kg i.p. + 0.4 ml/kg i.m.; Dopaser/Calier, Spain) and
body temperature was maintained constant with a heating pad
(37 ± 0.5◦C). The level of anesthesia was constantly checked by
tail pinch reflex and, if necessary, reinforced with 10% of the
initial dose. Following standard coordinates (AP = −5.6 mm,
LL = ± 4.5 mm, H = −3.0 mm; Paxinos and Watson, 1997),
stereotaxic surgery was performed to implant one cannula
(12 mm 23G stainless steel needles; BD, Brazil) in the left dorsal
hippocampus and two monopolar recording electrodes (13 mm
tungsten wire coated with Teflon 60 µm diameter; AM system
Inc., USA), one in the right and one in the left dorsal hippocampal
hilus. A silver wire welded to a micro-screw (placed in the suture
of the parietals and occipital bones) served as reference electrode.
All electrodes and the cannula were fixed in the skull using
dental cement. Animals were allowed to recover for 7 days before
administration of pilocarpine, CBD, or vehicle.
Status epilepticus was induced by 1 µL pilocarpine
hydrochloride i.h. (2.4 mg/µL diluted in 0.9 % saline; Sigma-
Aldrich, USA), injected with a microsyringe (10 µL Hamilton
syringe; Sigma, USA) connected to a polyethylene tube (30 cm,
PE10) and gingival needle (curved 13 mm, 30G; Injex, Brazil),
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at 1 µL/min flow. SE was kept for 2 h, and seizure was aborted
with sodium thiopental i.p. (30 mg/kg; Abbott, Brazil). CBD
(99.9% pure; STI Pharmaceuticals, Brentwood, UK) was prepared
10 mg/kg diluted in 98% saline (0.15 M NaCl) and 2% Tween 80
(Sigma-Aldrich, UK) and injected i.p. in a volume of 1 mL/kg,
1 h before SE induction (groups SE+CBDp and SE+CBDt).
Additionally, CBD was administered every 12 h up to euthanasia
in the SE+CBDt group. Rats from all groups were euthanized at
1 or 3 days post SE.
Control groups were rats that received either one injection of
vehicle i.p. (98% saline+ 2% Tween 80; VH group), one injection
of CBD (10 mg/kg i.p. in vehicle; CBD group), or one injection
of the vehicle before SE induction (SE group). All SE animals
were analyzed for SE onset latency and severity. Classification
of seizure severity was according to the modified Racine’s
scale: (1) mouth and facial movements, (2) head nodding, (3)
forelimb clonus, (4) rearing, (5) rearing and falling (Racine,
1972).
Gas Chromatography
The dose of CBD was chosen based on anticonvulsant effects
and pharmacokinetic studies (Karler et al., 1979; Turkanis et al.,
1979; Siemens et al., 1980; Consroe et al., 1982; Jones et al.,
2009). Gas chromatography has used to evaluate the CBD plasma
levels during the experiments and ensure CBD was present
during our experiment. Blood samples were collected from rat’s
tails 90 min after CBD injection for CBD, SE+CBDp, and
SE+CBDt groups at day 0 (i.e., SE induction day) to assess
acute CBD presence, and at days 1 and 3 for SE+CBDp and
SE+CBDt. Gas chromatography evaluation followed previously
established protocols for CBD detection (Karschner et al., 2010;
Andrews and Paterson, 2012). CBD was detectable in the plasma
at day 0 (Supplementary Figure S1). One and three days
after administration, CBD plasma concentration was reduced
or absent in SE+CBDp rats, whereas increasing levels of CBD
were detected in the plasma of SE+CBDt rats (Supplementary
Figure S1). SE+CBDt rats also had a higher variability in CBD
plasma levels than SE+CBDp rats. Thus, CBD was detectable in
almost all rats from the SE+CBD groups within the temporal
window of our experiment.
Electrophysiological Analysis
Spontaneous LFPs were recorded 7 days after the animal surgery.
Experiments were performed in a homemade wooden box
placed inside a Faraday cage, which allowed free movement
of the rats (Supplementary Figure S2). Analogic signal were
amplified, filtered (×100, 0.5–500 Hz, P55 pre-amplifier, Grass
Technologies), and digitized (sampling rate of 400 Hz) utilizing
an analogic-digital converter (Powerlab/16s; ADInstruments,
Inc., Australia), connected to a computer, and recorded on
LabChart 7.2 software (ADInstruments, Australia). Concomitant
video recording was performed with a digital camera (webcam)
positioned inside the wooden box (video-EEG).
LFP recording was carried out during 20 min (baseline
recording or after administration CBD) followed by and
additional 2-h recording after SE induction. Oscillatory activities
of SE groups (SE, SE+CBDp, and SE+CBDt) were monitored
1 h per day, at day one and day three after SE. Signal artifacts
(i.e., events with amplitude 2.5 times superior to the standard
deviation of the segment) were removed from LFP, and data was
analyzed using custom-made MATLAB scripts (The Mathwork,
Natick, MA, USA). Power spectra densities (PDs) were calculated
using mtspectrumc scripts from Chronux package1. Chronux
parameters used were: f pass = [0 100], tapers = [3 5], err = [0
0.05], trialave = 1, pad = 0 (Lopes-Aguiar et al., 2013). In
addition, relative power spectra (normalized to the PSD sum
across frequencies) in delta (0.5–4 Hz) and theta (4–10 Hz)
were calculated. The relative (normalized) power band estimates
the spectral density at delta and theta in relation the entire
spectrogram (Moshel et al., 2013). Spectral energy from 58 to
62 Hz was excluded to avoid noise contamination. Power spectra
were compared among groups to evaluate the effect of CBD
treatment on oscillatory activity.
Open Field Test
Open field test was performed to evaluate the post ictal
locomotion of the rats. An activity monitor apparatus (Insight,
Brazil) was used to analyze total distance explored, the number
of vertical activities (the number of times an animal rises in its
hind limbs), time explored on the borders and center of the arena
(Supplementary Figure S3). The testing protocol consisted of
placing the animal in the center of the box (habituation) for 3 min
and then test for 8 min, according to previously tested protocols
(Wolf et al., 2016). After each test, open field was cleaned with
acetic acid (0.1% v/v). All data were automatically collected via
software (Insight, Brazil).
Histological Evaluation
One or three days after SE, rats were anesthetized with
sodium pentobarbital (80 mg/kg i.p.) and perfused intracardially
with 100 mL phosphate buffered saline (PBS, 0.1 M pH
7.4), followed by 250 mL 4% (w/v) paraformaldehyde in
PBS. Brains were then removed from skull, post-fixed by
immersion in 4% paraformaldehyde-PBS for 4 h, dehydrated
and embedded in paraffin. Eight-micrometer-thick coronal
sections (−3.3 to −3.6 mm from bregma) were mounted on
slides and submitted to Fluoro-Jade B (FJB) histochemistry
and NeuN immunohistochemistry for evaluation of neurons in
degeneration and neuronal density, respectively.
Fluoro-Jade B histochemistry followed published protocol
(Schmued et al., 1997; Do Val-da Silva et al., 2016). Brains
were deparaffinized, hydrated, and immersed in the following
sequence: NaOH 1% (w/v) solution in 80% (v/v) ethanol (5 min);
70% (v/v) ethanol (2 min); distilled water (2 min); potassium
permanganate 0.06% (w/v) (15 min); two baths of distilled
water (1 min); 0.01% Fluoro-Jade B (Histo-Chem Inc., USA) in
0.01% acetic acid (30 min); and three baths of distilled water
(1 min). Sections were dehydrated and mounted with Krystalon
(Harleco/EMD Millipore, USA).
Adjacent coronal sections were submitted to
immunohistochemistry for the detection of NeuN epitope
with an anti-mouse antibody (code MAB377, Chemicon/EMD
1http://chronux.org/
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Millipore, USA), following previously published protocols
(Peixoto-Santos et al., 2012; Kandratavicius et al., 2014b).
Briefly, sections were submitted to endogenous peroxidase
block, microwave antigenic retrieval with 50 mM Tris-HCl
pH 9.6, and overnight NeuN antibody solution in skim milk
blocking buffer at 1:1,000 dilution. Primary antibody detection
was done with rabbit anti-mouse IgG (E0354, Dako, Denmark)
in blocking buffer (1:200), avidin-biotin-peroxidase kit (Elite
ABC kit, Vector, USA) amplification, and diaminobenzidine
(DAB, Pierce/ThermoFisher, USA) as a chromogen. Sections
were dehydrated and mounted with Krystalon (Harleco,
USA).
Micrographs from hippocampal subfields were collected with
AxioVision software and MR AxioCam 15MP coupled to an
Axioscope A1 microscope (Zeiss, Germany). FJB positive (FJB+)
cells were counted in 30 squares of 2,500 µm2 in the contralateral
and ipsilateral hilus, CA3, and CA1 subfields. NeuN positive cells
were counted in 12 squares of 2,500 µm2 in granule cell layer, 6
squares of 2,500µm2 in the hilus, and 10 squares of 2,500µm2 in
CA3 and CA1 subfields, and neuron density was estimated with
Abercrombie correction, as described elsewhere (Do Val-da Silva
et al., 2016).
Statistical Analysis
Student’s t-test or ANOVA followed by the Sidak post hoc test
were used for parametric variables, whereas non-parametric
variables were evaluated with Mann–Whitney’s. For analysis over
time between different groups, we used two-way ANOVA for
repeated measures mixed model (RM ANOVA) followed by a
Sidak post hoc test. In the results section, the mention of Sidak
post hoc test was omitted, but this post hoc test was applied to
all ANOVA tests and is mentioned in the figure captions. All
statistical procedure was performed using SPSS 17. Statistical
significance was considered at p< 0.05.
RESULTS
Behavioral Effects of CBD
As expected, VH and CBD groups showed no behavioral change.
A higher number of SE+CBD rats did not developed SE when
compared to SE group (35.1% vs. 15.9%; χ2, p = 0.025). The
SE+CBD groups, when compared to SE group, had increased
latency to SE (44 ± 3 min vs. 20 ± 2 min; t-test, p < 0.001;
Figure 1A) and lower SE severity (Racine 3 vs. Racine 4; Mann–
Whitney, p< 0.001; Figure 1B). Moreover, none of the SE+CBD
rats presented Racine 5 seizures or died, whereas 36.1% of rats
from SE group had Racine 5 seizures and one rat died during
SE.
Locomotory activity was assessed to evaluate post-ictal
changes (i.e., post ictal lethargy) in rats submitted to pilocarpine-
induced SE. Compared to controls (VH and CBD) and
SE+CBDp, SE rats had less vertical exploratory behavior 1 day
after SE (ANOVA; p ≤ 0.02; Figures 2A–F), whereas at day
3 SE had lower vertical exploratory activity than VH group
(ANOVA, p = 0.008; Figure 2A). There was no difference
between groups regarding total exploratory behavior or time
FIGURE 1 | Cannabidiol (CBD) modulation of SE latency and severity.
Rats submitted to CBD before SE induction (SE+CBD, green bar) had
increased latency to SE onset (A) and decreased SE severity (B), compared
to rats not injected with CBD (SE group, black bar). The ∗ indicates difference
from SE group, and data are expressed as mean ± standard error.
spent on the arena borders vs. arena center (data not shown).
Therefore, CBD treatment modulated the behavioral features of
pilocarpine-induced SE and normalized the post-SE locomotory
activity in the SE+CBDp group shortly after SE.
Electrophysiological Modulations of CBD
The LFP recording of animals during SE showed increased
time to contralateral epileptiform afterdischarges onset in
SE+CBD groups compared to SE group (8.09 ± 2.42 min
vs. 2.10 ± 0.52 min; t-test, p = 0.04; Figure 3A). There
was no difference regarding afterdischarge onset ipsilateral
to the pilocarpine microinjection (7.63 ± 2.52 min vs.
2.36 ± 0.46 min; t-test, p = 0.06). A qualitative evaluation of
the raw LFP recording as well as the whole frequencies from
0.5–25 Hz shows differences in electrographic activity between
the SE and the SE+CBD groups (Figure 3B). Amongst the
frequencies in the 0.5–25 Hz interval, increased hippocampal
delta (0.5–4 Hz) and theta (4–10 Hz) frequencies are hallmarks
of ictal electrographic activity, as mentioned above. Thus,
ictal powers of these low-frequency oscillations are relevant to
understand the neuroprotective actions of CBD during seizures
and the post-ictal electrographic changes in the pilocarpine-
induced SE rat model. SE+CBD groups had lower relative power
in theta frequency contralateral to pilocarpine microinjection,
when compared to SE group, at 40–80 min (0.12 ± 0.013 vs.
0.22 ± 0.02; RM ANOVA, p = 0.01) and in the full block of time
(0.11± 0.009 vs. 0.17± 0.01; RM ANOVA, p= 0.016; Figure 3C).
Contralateral delta band oscillation changed over time (RM
ANOVA, p < 0.001), with a trend toward difference between
SE+CBD and SE groups at 0–20 min (0.36± 0.06 vs. 0.54± 0.04)
Frontiers in Pharmacology | www.frontiersin.org 4 March 2017 | Volume 8 | Article 131
fphar-08-00131 March 20, 2017 Time: 19:28 # 5
Do Val-da Silva et al. CBD Effects in Pilocarpine-Induced SE
FIGURE 2 | CBD action on vertical activity of rats submitted to
pilocarpine-induced SE. One day after pilocarpine-induced SE, SE rats had
a reduced vertical exploratory activity (measured as number of rises in the rat’s
hind limbs), when compared to the controls (VH and CBD), and with SE rats
pretreated with CBD (SE+CBDp). Representative images from the activity
monitor showing the location of each rise from a VH rat (B), a CBD rat (C), a
SE rat (D), a SE+CBDp rat (E), and a SE+CBDt rat (F). The red dots in B–F
indicate the places within the activity monitor where the rats rose on its hind
limbs. Three days after SE, SE rats had low vertical exploratory activity only
when compared to VH group (A). The ∗ indicates difference from SE group
and data are expressed as mean ± standard error.
but no difference in the full block of time (Figure 3D). There was
no difference in relative powers in delta and theta frequencies
in the hippocampus ipsilateral to pilocarpine injection, when
comparing the SE+CBD and SE groups (RM ANOVA; data not
shown).
The evaluation of spectral power 1 and 3 days after SE showed
continuous drop in relative power of delta frequencies of the
SE+CBD groups, with more prominent drop in the SE+CBDp
group (compare Figure 3D full block of time with Figure 4A),
whereas the relative power in theta frequency of SE group
dropped over time while the theta frequencies of SE+CBDp and
SE+CBDt groups increased (compare Figure 3C and Figure 4B).
At day one, there was no difference between SE, SE+CBDp,
and SE+CBDt regarding contralateral relative power in delta
(Figure 4A) or theta frequencies (Figure 4B). At 3 days post-
SE, SE+CBDp had lower contralateral relative power in delta
band compared to SE group (0.34 ± 0.03 vs. 0.47 ± 0.02; RM
ANOVA, p = 0.02; Figure 4A). There was no difference between
SE+CBDp, SE+CBDt, and SE in the theta frequency on day
three (Figure 4B). There was also no difference in the ipsilateral
delta and theta frequencies between the groups at 1 or 3 days
(RM ANOVA, data now shown). CBD and VH groups had no
difference in baseline or in delta and theta frequencies (data
FIGURE 3 | Cannabidiol effects on spontaneous local field potential
(LFP) of the contralateral hippocampus during SE. CBD injection prior to
SE (SE+CBD group, green bars) increased afterdischarge latency (A),
compared to untreated rats (SE group, black bars). Relative power of
frequencies 0.5–25 Hz from a representative SE rat (black line) and a
SE+CBD rat (green line) and a raw LFP hippocampal recording from the same
examples (B). Evaluating the LFP recording in time blocks, SE+CBD had a
lower relative power in theta between 40 and 80 min and in the whole SE (C).
As for delta oscillation, SE+CBD had a trend toward lower relative power in
delta in the first 20 min of SE but no difference in the whole SE recording (D).
The ∗ indicates difference from SE group, t indicates trend toward difference,
and data are expressed as mean ± standard error.
not shown). In summary, CBD increased afterdischarge latency
and prevented some of the theta and delta changes seen in the
pilocarpine-induced SE.
Neuroprotective Effects of CBD in the
Hippocampus
Acutely after SE, neurons in the hippocampus often enter a
process of degeneration that leads to neuron loss over time.
In our study, neurodegeneration was measured by presence
and number of Fluoro-Jade B positive (FJB+) cells. No FJB+
cells were seen in the control groups VH and CBD, 1 or
3 days after vehicle or CBD injection. SE group had a high
number of FJB+ cells in the contralateral and ipsilateral hilus,
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FIGURE 4 | Relative power in delta and theta frequencies 1 and 3 days after SE induction. CBD pretreatment (SE+CBDp, medium green bars) reduced the
relative power in delta, compared to SE group 3 days after SE (black bar) (A; RM ANOVA followed by Sidak post hoc test). There was no difference between SE,
SE+CBDp, and SE+CBDt in delta frequency 1 day post-SE and in theta frequency 1 or 3 days post-SE (B). The ∗ indicates difference from SE group and data are
expressed as mean ± standard error.
CA3, and CA1 at 1 (Figure 5) or 3 days (Figure 6) post
SE induction. CBD injection significantly reduced SE-induced
neurodegeneration, as can be visually seen in the comparison
of SE+CBDp (B,E) and SE+CBDt (C,F) with SE hilus (A,D) of
Figures 5, 6. In agreement with the visual evaluation, SE+CBDp
and SE+CBDt had significantly lower FJB+ cells in the hilus
(ANOVA, p ≤ 0.001) and CA3 (ANOVA, p ≤ 0.03) of the
ipsilateral and contralateral hippocampus, compared to SE group,
1 day after SE (Figures 5G,H). Three days after pilocarpine-
induced SE (Figures 6G,H), SE+CBDp and SE+CBDt groups
had lower FJB+ cells only in the contralateral hilus (ANOVA,
p ≤ 0.014), compared to SE group. All SE groups (SE,
SE+CBDp, and SE+CBDt) had FJB+ cells in ipsilateral or
contralateral CA1 subfield at 1 and 3 days after SE, with no
statistical difference between groups. Thus, CBD reduced the
neurodegeneration common to the pilocarpine-induced SE rat
model.
To evaluate neuron loss following SE, we analyzed neuron
density, measured as NeuN positive cell density, at 1 and 3 days
post-SE. One day after SE induction, SE group had lower neuron
density than the controls (VH and CBD) in the contralateral
(Figure 7A) and ipsilateral (Figure 7B) hilus, CA3, and CA1
(ANOVA, p < 0.001), as well as in the ipsilateral granule cell
layer (ANOVA, p< 0.001). CBD injection prevented SE-induced
neuron loss, as SE+CBDp, and SE+CBDt groups had higher
neuron density than SE group in contralateral (Figure 7A) and
ipsilateral (Figure 7B) hilus, CA3, and CA1 (ANOVA, p< 0.001),
and in ipsilateral granule cell layer (ANOVA, p < 0.001;
Figure 7B). Moreover, SE+CBDp and SE+CBDt groups had
similar neuron density than the control groups in almost all
hippocampal subfields evaluated. Only in contralateral CA3 and
CA1, SE+CBDp group had higher neuron density than CBD
and SE+CBDt (ANOVA, p < 0.006), and than VH, CBD, and
SE+CBDt (ANOVA, p < 0.03; Figure 7A), respectively. There
was no difference between groups in contralateral granule cell
layer.
The 3 days post-SE histological evaluation showed lower
neuron density in the SE group, compared to the controls (VH
and CBD), in contralateral granule cell layer and in contralateral
and ipsilateral, hilus, CA3, and CA1 (ANOVA, p < 0.01;
Figures 8A,B, 9). SE had also lower neuron density than CBD in
the ipsilateral granule cell layer (ANOVA, p= 0.042). SE+CBDp,
and SE+CBDt groups had higher neuron density than SE group
in the contralateral and ipsilateral hilus, CA3, and CA1 (ANOVA,
p ≤ 0.04). In the contralateral hippocampus (Figure 8A),
SE+CBDt had lower neuron density than CBD in the granule
cell layer and CA1 (ANOVA, p ≤ 0.037), and than SE+CBDp in
the granule cell layer (ANOVA, p = 0.048). In ipsilateral granule
cell layer (Figure 8B), SE had lower neuron density than CBD
and SE+CBDp (ANOVA, p ≤ 0.042) SE+CBDt group had lower
neuron density than SE+CBDp (ANOVA, p< 0.04). In ipsilateral
CA3 (Figure 8B), SE+CBDp also had higher neuron density
than CBD and SE+CBDt (ANOVA, p ≤ 0.038). SE+CBDt had
lower neuron density than VH, CBD, and SE+CBDp in ipsilateral
CA1 (ANOVA, p ≤ 0.04; Figure 8B). Our findings indicated that
CBD administration, both before (SE+CBDp) and before and
after (SE+CBDt) pilocarpine-induced SE protected hippocampal
sector from neuron loss up to 3 days after the SE.
DISCUSSION
In the present study, CBD had protective effects on pilocarpine-
induced SE, reducing the number of rats that developed SE
following intrahippocampal pilocarpine injection, increasing SE
behavioral latency, and reducing SE severity from Racine 4 to
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FIGURE 5 | Protective action of CBD over neuronal degeneration 1 day after pilocarpine-induced SE, evaluated by Fluoro-Jade B (FJB) staining.
(A–F), representative micrographs from the contralateral (A–C) and ipsilateral (D–F) hilus of a SE rat (A,D), SE+CBDp rat (B,E), and a SE+CBDt rat (C,F). Whereas
SE rats present higher number of FJB positive neurons in both hilus (arrows in A,D), CBD treated rats had only a few FJB positive neurons (B,C,E,F). Both the
contralateral (G) and ipsilateral (H) hippocampus of SE+CBDp (medium green bars) and SE+CBDt (dark green bars) had a lower number of FJB positive neurons in
the hilus and CA3, compared to SE group (black bars; ANOVA followed by Sidak post hoc test). The white bar in F indicates 100 µm and the ∗ indicates differences
from SE group. Data were presented as mean ± standard error.
Racine 3. CBD also affected contralateral LFP, increasing the
latency to epileptiform discharges and reducing the relative
powers in delta and theta oscillations. Only in the pretreatment
group (SE+CBDp), CBD reduced contralateral relative delta
oscillations up to 3 days after SE and increased the exploratory
behavior 1 day after SE. Finally, CBD preventive (SE+CBDp) and
CBD preventive and therapeutic treatment (SE+CBDt) reduced
neuronal degeneration and neuron loss both in the ipsilateral and
contralateral hippocampus.
Physiologically, cannabinoids have been suggested to play a
major role in tissue homeostasis, modulating neurotransmission
in the central nervous system (Marsicano and Lutz,
2006). Endocannabinoids are synthesized in response to
hyperexcitability and, acting at presynaptic receptors, modulate
the release of neurotransmitters (Lutz, 2004; Marsicano and
Lutz, 2006). Similarly to endocannabinoids, CBD can modulate
neuronal excitability via CB1-depentent and CB1-independent
pathways (Pertwee, 2008). The most relevant effect of CBD
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FIGURE 6 | Protective action of CBD over neuronal degeneration 3 days after pilocarpine-induced SE, evaluated by Fluoro-Jade B (FJB) staining. (A–F),
representative micrographs from the contralateral (A–C) and ipsilateral (D–F) hilus of a SE rat (A,D), SE+CBDp rat (B,E), and a SE+CBDt rat (C,F). Similar to 1 day
evaluation, SE rats presented higher number of FJB positive neurons in both hilus (arrows in A,D), compared to CBD-treated rats (B,C,E,F). SE+CBDp (medium
green bars) and SE+CBDt (dark green bars) had a lower number of FJB positive neurons in the contralateral hilus (G), compared to SE group (black bars), with no
difference in CA3 and CA1 contralateral (G), or in the ipsilateral hippocampus (H; ANOVA followed by Sidak post hoc test). The white bar in F indicates 100 µm and
the ∗ indicates differences from SE group. Data were presented as mean ± standard error.
on neuronal excitability is the regulation of intracellular
Ca2+ in hippocampal neurons during hyperexcitability
states (Ryan et al., 2009). Additional effects of CBD on
neurotransmission are the reduction of N-Methyl-D-Aspartate
receptor (NMDAR) NR1 subunit expression (Mao et al., 2015),
facilitation of serotoninergic 5-hydroxytryptamine receptor
1a (5-HT1a) dependent transmission (Campos et al., 2012;
Jones et al., 2012), and reduction of γ-aminobutyric acid
(GABA), serotonin, and norepinephrine uptake by synapses
(Banerjee et al., 1975). In line with these actions, studies
with chemically induced and electrically induced seizures
have shown anticonvulsant effects of CBD (Consroe and
Wolkin, 1977; Consroe et al., 1982; Jones et al., 2009, 2012).
In our study, CBD injection before pilocarpine-induced SE
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FIGURE 7 | Cannabidiol effects on hippocampal neuronal survival, 1 day after SE. Neuronal density, estimated in contralateral (A) and ipsilateral (B)
hippocampal sections from VH (white bars), CBD (light green bars), SE (black bars), SE+CBDp (medium green bars), and SE+CBDt (dark green bars) groups. All
groups had higher neuron density than SE group in the hilus, CA3, and CA1 subfields of contralateral (A) and ipsilateral (B) hippocampus (ANOVA followed by Sidak
post hoc test). In the contralateral hippocampus, SE+CBDp group had higher neuron density than CBD and SE+CBDt in CA3 and CA1. SE+CBDp had also higher
neuron density than VH group in the contralateral CA1 subfield. The groups VH, CBD, SE+CBDp, and SE+CBDt had also higher neuron density than SE group in
the ipsilateral granule cell layer. GCL, granule cell layer; HIL, hilus. The ∗ indicates differences from SE group, the † indicates difference from SE+CBDt group, the §
indicates difference from CBD group, and the # indicates difference from VH group. Data were presented as mean ± standard error.
doubled the latency to SE onset and reduced SE severity
and mortality. Moreover, one rat from SE+CBD groups
had spontaneous SE remission, which did not occur in
the SE group. In addition to the behavioral effects, CBD
delayed seizure spread for the contralateral side, increased
afterdischarges latency and reduced the relative powers in
delta and theta frequencies at the contralateral hippocampus.
In TLE patients, regardless of the specific neuropathological
changes, most patients present flattening of EEG activity,
fast activity associated with a reduction in amplitude as
the ictal pattern, followed by increased rhythmic delta and
theta activity during seizure development and propagation
(Pelliccia et al., 2013). Pathological delta and theta activities
are indicators of several neuropathological conditions, such
as ischemia, tumors, neurodegenerative diseases, and epilepsy
(Gloor et al., 1977; de Jongh et al., 2003; Babiloni et al., 2006;
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FIGURE 8 | Cannabidiol effects on hippocampal neuronal survival, 3 days after SE. Neuronal density, estimated in contralateral (A) and ipsilateral (B)
hippocampal sections from VH (white bars), CBD (light green bars), SE (black bars), SE+CBDp (medium green bars), and SE+CBDt (dark green bars) groups. The
groups VH, CBD, SE+CBDp, and SE+CBDt had higher neuron density than SE group in contralateral (A) and ipsilateral (B) hilus, CA3, and CA1 subfields (ANOVA
followed by Sidak post hoc test). In the contralateral granule cell layer, the groups VH, CBD, and SE+CBDp had higher neuron density than SE, and the groups CBD
and SE+CBDp had higher neuron density than SE+CBDt. CBD group had also higher neuron density than SE+CBDt in contralateral CA1. In the ipsilateral granule
cell layer (B), the group CBD had higher neuron density than SE, and the group SE+CBDp had higher neuron density than SE and SE+CBDt groups. In CA3,
SE+CBDp group had higher neuron density than CBD and SE+CBDt groups, and in CA1 the groups VH, CBD, and SE+CBDp had higher neuron density than
SE+CBDt group. GCL, granule cell layer; HIL, hilus. The ∗ indicates differences from SE group, the § indicates difference from CBD group, the † indicates difference
from SE+CBDt group. Data were presented as mean ± standard error.
Pelliccia et al., 2013). In an ischemia model, 5-mg/kg CBD
injection 5 min after bilateral carotid occlusion prevented
the increase in delta frequency seen in the vehicle-treated
ischemic gerbils (Braida et al., 2003). However, one study
showed that clinical improvement is not always followed by EEG
improvement in drug-resistant patients (Cunha et al., 1980).
Our results suggest that CBD exerts its therapeutic effect by
modulating not only the behavioral characteristics of seizures
but also the oscillatory activity in the power spectrum of SE
model.
There are limited clinical studies on CBD anticonvulsant
properties. A prospective, double-blind, controlled study
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FIGURE 9 | Representative micrographs from contralateral (A–O) and
ipsilateral (A’–O’) hilus (A–E,A’–E’), CA3 (F–J,F’–J’), and CA1 (K–O,K’–O’) of
VH (A,A’,F,F’,K,K’), CBD (B,B’,G,G’,L,L’), SE (C,C’,H,H’,M,M’), SE+CBDp
(D,D’,I,I’,N,N’), and SE+CBDt (E,E’,J,J’,O,O’) rats 3 days after SE,
submitted to NeuN immunohistochemistry. See the intense neuron loss
throughout the hippocampal subfields of a SE rat, both ipsilateral and
contralateral to pilocarpine injection, compared to VH and CBD controls. The
neuroprotective effect of CBD on SE-induced neuron loss is visible in the
SE+CBD groups, as statistically confirmed in Figure 8. HIL, hilus; IPSI,
ipsilateral side to pilocarpine injection; CONTRA, contralateral side to
pilocarpine injection. The bar in O’ indicates 100 µm.
conducted with 15 drug-resistant TLE patients showed that
CBD increased antiepileptic drug efficacy, promoting seizure
remission in 50% of cases and reducing seizure frequency in
37.5% of patients (Cunha et al., 1980). Another study showed
reduction in seizure frequency after CBD administration
(Trembly and Sherman, 1990). In contrast, a randomized study
with drug-resistant cases failed to indicate an anticonvulsant
effect of CBD (Ames and Cridland, 1986). More recently,
an open-label study showed that CBD, co-administered with
antiepileptic drugs, reduces seizure frequency in severe drug-
resistant epilepsies such as Dravet syndrome (Devinsky et al.,
2016). CBD also reduced seizure frequency by half in tuberous
sclerosis cases (Hess et al., 2016). These clinical studies,
although involving a small number of drug-resistant patients,
showed the potential action of CBD as an anticonvulsant,
especially if added to the traditional antiepileptic drug therapy.
New studies should evaluate the potential benefits of CBD
administration during the latent period of TLE. Unlike
most epilepsies, patients with TLE often present a history
of a seizure in the early childhood, followed by a latent
period that culminates with the appearance of spontaneous
recurrent seizures later in life (Engel, 1996). This latent period,
when several plastic changes take place in the temporal lobe
(Pitkanen and Sutula, 2002), is an important therapeutic
window to prevent seizure recurrence in TLE. Moreover, as
an adjuvant to the already established therapeutic strategies,
CBD could also have an important impact in SE management,
a medical emergency with high mortality, morbidity, and
often associated with significant neuron loss (Neligan and
Shorvon, 2009; Trinka et al., 2015; Grover et al., 2016). In
light of the protective effects against pathological oscillatory
changes and neurodegeneration seen in our study, CBD could
improve SE management and latent period treatment of epilepsy
patients.
Impaired cognition, lethargy, headaches, and even depression
can follow the seizures in drug-resistant epilepsy patients (Fisher
and Schachter, 2000). The pilocarpine-induced SE model often
presents a post-ictal lethargy state, with a significant decrease
in exploratory activity (Turski et al., 1983b; Prut and Belzung,
2003). Evidence of functional recovery promoted by CBD
treatment come from ischemia models, where CBD improved
the neurological function scores, the motor coordination, and
reduced the hyper locomotory behavior up to 3 days after the
ischemic brain insult (Braida et al., 2003; Hayakawa et al.,
2008). The protection of neurological function seen in ischemia
models can be extended to the protective effects described in
mesial TLE (MTLE). However, in our study, only the pretreated
group (SE+CBDp) had decreased prostration/post-ictal lethargy,
as shown by increased vertical exploratory activity. Although
SE+CBDp group received only one CBD injection before SE
induction, detectable levels of CBD were seen in the plasma
up to 3 days post-SE, as shown by the gas chromatography
evaluation. The presence of CBD in the single dose group was
expected, given that the half-life of CBD elimination has been
estimated between 2 and 5 days (Consroe et al., 1991). As for
the SE+CBDt group, there was no effect of CBD treatment
on delta activity and post-ictal prostration. Since CBD acts
with an inverted U-shaped dose-response curve (Guimaraes
et al., 1990; Campos et al., 2012; Levin et al., 2014; Nazario
et al., 2015), the higher CBD plasma levels of SE+CBDt could
be responsible for the lack of CBD effect on exploratory and
electrographic activities after SE, if compared to the single
treatment group SE+CBDp, which had lower doses of plasma
CBD.
Patients and an animal model of MTLE often present
neurodegenerative damage in different brain areas (Araujo et al.,
2006; Diniz et al., 2011; Kandratavicius et al., 2015; Peixoto-
Santos et al., 2015; Wolf et al., 2016). In particular, severe
loss of hilar interneurons and pyramidal neurons in CA3 and
CA1 is commonly seen in the hippocampus of MTLE patients
and animal models (Turski et al., 1983a; Leite et al., 1996;
Covolan et al., 2000). The neuroprotective actions of CBD
were demonstrated in experimental models of cerebral ischemia,
where CBD treatment reduced the infarct size and prevented
hippocampal neuron loss, especially in the CA1 and hilus
subfields (Braida et al., 2003; Hayakawa et al., 2008; Schiavon
et al., 2014). We can transpose these protective effects of CBD
in ischemia models for epilepsy since these disorders share
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common mechanisms of neuronal loss involving Ca2+ and
excitotoxicity mechanisms (Auer and Siesjo, 1988). In epilepsy,
the neuronal loss is a dynamic process that comprises
multiple factors. Among these factors, excessive Ca2+ influx
mediated by voltage-gated and NMDAR activation during
prolonged seizures, increased reactive oxygen species production,
increased Zn2+ accumulation in neurons, amongst others (Choi,
1992; Cole et al., 2000). The elevation of intracellular ions
activates several biochemical cascades and proteases, lipases,
and endonucleases, which will promote degeneration and cell
death (Choi, 1992). Since cannabinoids can regulate intracellular
Ca2+ homeostasis (Drysdale et al., 2006; Ryan et al., 2009;
De Petrocellis et al., 2011), we can speculate that Ca2+
mechanisms are crucial for the neuroprotective action of CBD.
Other significant neuroprotective effects of CBD are modulation
of neurotransmitters’ release, modulation of NMDA receptor
activation, and inhibition of reactive astrogliosis (Lutz, 2004;
Marsicano and Lutz, 2006; Schiavon et al., 2014). In the present
study, CBD administration protected hippocampal neurons from
the degeneration and death common to pilocarpine-induced
SE.
Some limitations of our study must be addressed. Published
data suggest that greater intensity of seizures in the acute phase
of SE increased the chance to develop recurrent seizures in the
chronic phase (Lemos and Cavalheiro, 1995). Since treatment
with CBD attenuated seizure severity during SE, it is expected
that CBD treatment attenuates the severity of the chronic phase
of the pilocarpine rat model of TLE. Thus, a further study
should evaluate the effect of CBD pre-SE treatment in the
spontaneous seizure frequency of the pilocarpine-induced SE
model. Moreover, future studies should also evaluate if the
neuroprotection promoted by this brief CBD treatments would
remain in the chronic period without the need of further
CBD injections. Finally, an important limitation of our study
was the lack of a post-SE CBD treatment only (i.e., without
the pre-SE CBD injection). This group would be crucial for
evaluation the add-on effect of CBD in the human SE and in
the post initial precipitant injury management, as commented
above.
CONCLUSION
This study showed that CBD treatment reduces the behavioral
severity and oscillatory electrographic changes of SE, the
post-ictal lethargy, and the neuronal loss associated with the
pilocarpine-induced SE rat model. More studies are needed to
understand the specific mechanisms of action related to the
neuroprotective and anticonvulsant effects of CBD in epilepsy.
AUTHOR CONTRIBUTIONS
Conceived and designed the experiments: JL, JH, JC, and
RD. Performed the experiments: RD, RS, IE, and JD.
Analyzed the data: RD, JP-S, LK, IE, and JD. Contributed
reagents/materials/analysis tools: BSD, MA, AZ, JC, JH, and JL.
Wrote the paper: RD, JP-S, LK, AZ, JC, JH, and JL.
FUNDING
This work was supported by Fundacao de Amparo a Pesquisa
do Estado de Sao Paulo (FAPESP, processes #2015/20840-9
and #2016/17882-4), Conselho Nacional de Desenvolvimento
Cientifico e Tecnologico (CNPq, processes #42702/2011-0
and # 423977/2016-4) and CNPq/MS/SCTIE/DECIT (processes
#466995/2014-8 and #466805/2014-4). AWZ, JPL, JECH, and
JAC are recipients of fellowship awards from CNPq.
ACKNOWLEDGMENT
We would like to thank Antonio Renato Meirelles e Silva and
Geraldo Cassio dos Reis for their excellent technical support.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fphar.
2017.00131/full#supplementary-material
FIGURE S1 | Cannabidiol (CBD) plasma levels. CBD plasma concentration
pre- and post-SE induction, measured with liquid phase gas chromatography. At
day 0 (pre-SE), all rats injected with CBD (groups CBD, SE+CBDp, and
SE+CBDt) had detectable CBD plasma 90 min post infusion. At days 1 and 3,
CBD levels decreased in the pretreatment group (SE+CBDp, medium green bar),
whereas rats infused with CBD pre-SE and every 12 h post-SE (SE+CBDt, dark
green bar) presented with increased CBD levels over time. The light green bar
indicates CBD only group, and graphs are expressed as mean ± standard error.
FIGURE S2 | Local field potential (LFP) register equipment. In A is shown a
rat attached to the register cable inside the register box, which in turn is attached
to an analogic-digital converter connected to a computer (B). Inside the box there
is a webcam, a light and a cooler (A).
FIGURE S3 | Representative photo of a rat inside the open field apparatus
(A). Rat movement is detected by a series of infrared sensors (arrows), being three
lower sensors that detect horizontal movement (white arrows) and one high
sensor (black arrow) that detects vertical movements (i.e., rises). The apparatus is
attached to a computer, and the software provided an image of the horizontal
movement of the rats inside the box (B) and the place and number of rises (C).
The software also provides the distance and velocity of every animal in a.txt file
(not shown).
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